Latest Capital Raising News

Ridley Corporation Limited reported a solid FY25 with revenue up 3.1% to $1.3 billion and net profit after tax rising 8.7% to $43.3 million. The company declared a fully franked final dividend of 5.00 cents per share, signaling confidence in its diversified growth strategy.

IPH Limited reported a 13.2% rise in net profit after tax to $68.8 million for FY25, driven by strategic acquisitions in Canada and organic growth across Asia-Pacific. Revenue surged 16.5% to $710.3 million despite inflationary pressures and operational challenges.

IPH Limited reported a robust FY25 with revenue rising 16.6% to $710.3 million and net profit after tax up 13.2% to $68.8 million, driven by strategic acquisitions and a pivot towards organic growth and AI integration.

Goodman Group delivered a robust FY25 performance, with operating profit rising 13% to $2.31 billion and a 9.8% increase in operating earnings per security. The company’s expanding data centre portfolio and strong capital position set the stage for continued growth.

QuickFee Limited posted a 25% increase in revenue to A$25.3 million for FY25, driven by strong growth in both Australia and the US, alongside a positive underlying EBTDA of A$2.4 million before a one-off credit loss provision.

St Barbara Limited reported a $52 million underlying loss for FY25, driven by investments in its Simberi Expansion Project and operational challenges. The company classified its Atlantic operations as discontinued, recognizing a $38 million impairment, while completing a $100 million capital raise to support growth.

Mount Ridley Mines Limited has announced a pro-rata entitlement offer to raise up to $596,842, accompanied by free attaching options, alongside a $234,000 placement aimed at funding key exploration projects and working capital.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Astron Corporation has completed its redomicile from Hong Kong to Australia, launching Astron Limited (Aus NewCo) as the new ASX-listed parent company with a 2-for-1 share consolidation.

Centaurus Metals Limited has updated the timetable for its $3 million Share Purchase Plan, offering eligible shareholders in Australia and New Zealand shares at $0.36 each with free-attaching options exercisable at $0.50.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.